Administration Instructions for Abilify Injectable
For immediate-release intramuscular (IM) injection used for acute agitation, administer 9.75 mg as a deep intramuscular injection into the muscle mass, injected slowly; for long-acting injectable (LAI) depot formulations, use either a one-injection start with 14 days of oral supplementation OR the newer two-injection start regimen with minimal oral supplementation. 1
Immediate-Release IM Injection (Acute Agitation)
Dosing and Administration
- Recommended dose: 9.75 mg IM for agitation associated with schizophrenia or bipolar mania 1
- Lower dose option: 5.25 mg may be considered when clinical factors warrant 1
- Repeat dosing: If agitation persists, cumulative doses up to 30 mg/day may be given, with injections spaced at least 2 hours apart 1
- Maximum: Do not exceed 30 mg/day or give injections more frequently than every 2 hours 1
Injection Technique
- Route: Intramuscular only - do not administer intravenously or subcutaneously 1
- Method: Inject slowly, deep into the muscle mass 1
- Preparation: Inspect visually for particulate matter and discoloration before administration 1
Volume Requirements
| Dose | Volume to Draw |
|---|---|
| 5.25 mg | 0.7 mL |
| 9.75 mg | 1.3 mL |
| 15 mg | 2.0 mL |
Transition to Oral Therapy
Switch to oral aripiprazole (10-30 mg/day) as soon as clinically indicated after IM injection for acute agitation 1
Long-Acting Injectable (LAI) Depot Formulations
Two Starting Regimen Options
Option 1: One-Injection Start (OIS) - Traditional Method
- Initial injection: 400 mg IM depot 2
- Oral supplementation: Continue oral aripiprazole for 14 consecutive days after first injection 2
- Maintenance: 400 mg every 4 weeks (single decrease to 300 mg permitted) 2
Option 2: Two-Injection Start (TIS) - Newer Simplified Method
- Initial regimen: Two 400 mg injections administered on the same day 3, 4
- Oral supplementation: Single 20 mg oral dose of aripiprazole on the same day as injections 3, 4
- Maintenance: Continue with monthly 400 mg injections 3
The two-injection start regimen is pharmacokinetically advantageous, maintaining serum levels within the therapeutic window while avoiding peaks above the window that may expose patients to toxicity, as observed with the one-injection start 3. This newer regimen has demonstrated comparable safety and tolerability to the traditional method in real-world clinical practice 4.
LAI Injection Technique (Aripiprazole Lauroxil Formulation)
Critical steps for proper administration 5:
- Resuspension: Tap and shake the prefilled syringe vigorously to resuspend drug particles before injection
- Injection speed: Use rapid injection speed (not slow injection)
- Route: Deep intramuscular injection
- Rationale: The aqueous-based suspension formulation requires these specific techniques to ensure proper drug delivery and slow release into plasma 5
Dosage Adjustments
Drug Interactions Requiring Dose Reduction
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): Reduce dose to one-half usual dose 1
- CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine): Reduce dose to one-half usual dose 1
- Combined CYP3A4 and CYP2D6 inhibitors: Reduce dose to one-quarter (25%) of usual dose 1
Special Populations
- CYP2D6 poor metabolizers: Reduce initial dose to one-half (50%) of usual dose 1
- Older or frail patients: Use lower doses and titrate gradually 6
- Hepatic impairment: Reduce dose 6
Common Pitfalls to Avoid
- Do not confuse formulations: Immediate-release IM for acute agitation uses different dosing than LAI depot formulations
- Avoid IV or subcutaneous administration: All injectable forms are for IM use only 1
- Do not skip oral supplementation with one-injection LAI start - the 14-day overlap is essential to maintain therapeutic levels
- For LAI lauroxil formulation: Failure to properly resuspend the suspension or using slow injection speed will compromise drug delivery 5
- Monitor for transient side effects: Nausea, insomnia, and agitation typically occur in 10-20% of patients during the first 3-7 days but are manageable and resolve 7, 8
Monitoring Considerations
- Extrapyramidal symptoms: Aripiprazole has lower risk than first-generation antipsychotics but monitoring remains important 6
- QTc prolongation: Minimal risk (0 ms mean prolongation) compared to other antipsychotics 9
- Metabolic effects: Monitor BMI, waist circumference, and blood pressure weekly for 6 weeks after initiation, then at 3 months and annually 10